Teleflex Incorporated (NYSE: TFX) a leading global provider of medical devices for critical care, urology and surgery will showcase two of its advanced Arrow® Interventional Access Products at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Barcelona.

During the event, Teleflex will highlight both the Arrow® OnControl® Powered Bone Access System and the ARROW-Clark™ VectorFlow™ Chronic Hemodialysis Catheter, together with other technologically advanced products for interventional applications.

The Arrow® OnControl® Powered Bone Access System offers the ability to effectively1, safely and rapidly2 obtain high quality bone samples. Our bone lesion biopsy needle is designed specifically for multiple bone biopsies from a single cortical penetration. Using Teleflex’s patented handheld driver technology, the Arrow® OnControl® Powered Bone Access System provides interventional radiologists a fast reliable3 solution for accessing dense and hard-to-reach bone lesions.

The ARROW-Clark™ VectorFlow™ Catheter is the only catheter with an innovative tip designed to produce a helical, three-dimensional transition of blood entering and leaving the catheter.4 Designed for optimum performance, the ARROW-Clark™ VectorFlow™ Catheter (available in both retrograde and antegrade insertion platforms) is a tunneled hemodialysis catheter with symmetrical tip that is designed to reduce loss of lock solution (a contributing factor in reducing the risk of thrombus adherence), gives sustained high flows, minimizes recirculation and reduces the risk of platelet damage resulting from shear stress.5

During the CIRSE Congress on Sunday, September 11 and Monday, September 12, at 14:00 Prof. Dr. med. Roman Fischbach, Head of Radiology and Neuroradiology at Asklepios Klinik Altona, will lead in-booth sessions entitled "CT guided bone biopsy with the Arrow® OnControl® Powered Bone Access System. Clinical applications, technique and results."

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, ARROW-Clark, Deknatel, Hudson RCI, LMA, OnControl, Pilling, Rüsch, VectorFlow and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2016 Teleflex Incorporated. All rights reserved.

References:

1. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematology Reports 2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free article] [PubMed] verified March 2015.

2. Lee RK, Ng AW, Griffith JF. CT-guided bone biopsy with a battery-powered drill system: preliminary results. AJR Am J Roentgenol 2013;201(5):1093-5. doi:10.2214/AJR.12.10521. Available at: [PubMed] verified March 2015.

3. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices. Hematology Reports 2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free article] [PubMed] verified March 2015.

4. Clark T, et al. Computational Flow Dynamics and Preclinical Assessment of a Novel Hemodialysis Catheter. Seminars in Dialysis 2012;25(5):574-581. doi: 10.1111/j.1525-139X.2012.01052.*

5. Clark TWI, Isu G, Gallo D, Verdonck P, Morbiducci U. Comparison of symmetric hemodialysis catheters using computational fluid dynamics. Journal of Vascular and Interventional Radiology. 2015;26(2):252-259. doi: 10.1016/j.jvir.2014.11.004

Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836orMartina Teichmann-ZindlerDirector Marketing Communications International+49 (0)7151-406-538martina.teichmann@teleflex.com

Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Teleflex Charts.
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Teleflex Charts.